Avenue Therapeutics Reaches Final Agreement with the U.S. FDA for the Phase 3 Safety Study for IV Tramadol

Stock Information for Avenue Therapeutics Inc.

Loading

Please wait while we load your information from QuoteMedia.

More Recent News About Avenue Therapeutics Inc.

Avenue Therapeutics Announces Exercise of Warrants for $4.4 Million in Gross Proceeds
Avenue Therapeutics Announces Reverse Stock Split
Avenue Therapeutics to Host Virtual Key Opinion Leader (KOL) Event on April 4, 2024
Avenue Therapeutics Reports Full Year 2023 Financial Results and Recent Corporate Highlights
Avenue Therapeutics Receives Positive Listing Determination from Nasdaq
Avenue Therapeutics to Present BAER-101 Preclinical Data at American Society for Experimental Neurotherapeutics (ASENT) 2024 Annual Meeting
Sidoti Events, LLC's Virtual January Micro-Cap Conference
Avenue Therapeutics to Present at Sidoti January Micro-Cap Investor Conference

Market data content copyright © QuoteMedia. Data delayed at least 15 minutes unless otherwise indicated (view Delay Times for all exchanges). Filings and Fundamentals by Morningstar. Insiders by Morningstar (USA) and SEDI (CDN). Analyst ratings by Zacks. Terms of Use.